AquaBounty Technologies (NASDAQ:AQB – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare AquaBounty Technologies to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.
Volatility and Risk
AquaBounty Technologies has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, AquaBounty Technologies’ rivals have a beta of -1.88, meaning that their average stock price is 288% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for AquaBounty Technologies and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AquaBounty Technologies | 1 | 0 | 0 | 0 | 1.00 |
| AquaBounty Technologies Competitors | 9916 | 15312 | 45656 | 1602 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 126.25%. Given AquaBounty Technologies’ rivals stronger consensus rating and higher possible upside, analysts clearly believe AquaBounty Technologies has less favorable growth aspects than its rivals.
Valuation & Earnings
This table compares AquaBounty Technologies and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| AquaBounty Technologies | N/A | -$18.49 million | -1.30 |
| AquaBounty Technologies Competitors | $730.68 million | $11.52 million | -18.80 |
AquaBounty Technologies’ rivals have higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares AquaBounty Technologies and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AquaBounty Technologies | N/A | -147.07% | -43.18% |
| AquaBounty Technologies Competitors | -12,319.70% | -407.93% | -30.95% |
Summary
AquaBounty Technologies rivals beat AquaBounty Technologies on 9 of the 13 factors compared.
AquaBounty Technologies Company Profile
AquaBounty Technologies, Inc. is a biotechnology and aquaculture company focused on developing and producing land-raised Atlantic salmon. Its principal product is AquAdvantage salmon, a genetically engineered salmon designed to reach market size more quickly than conventional Atlantic salmon. The company has pursued land-based, contained aquaculture systems intended to reduce reliance on ocean-based farming and improve production efficiency. AquAdvantage salmon incorporates a growth-hormone gene from Chinook salmon and a regulatory sequence from ocean pout.
Receive News & Ratings for AquaBounty Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AquaBounty Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
